Development of Chronomers for narcotic antagonists.
The object of this program is to prepare a bioerodable naltrexone delivery system which can be implanted subcataneously in human and which can relieve the narcotic antagonist over 1-6 months at relatively constant and sufficient rates to block the euphoric effect of morphine based drugs. The system is composed of naltrexone uniformly dispersed in a solid hydropholic CHRONOMER matrix which undergoes predictable surface erosion when exposed to an aqueous medium. Kinetic studies in vitro have been carried out during the course of the program to determine the best composition for the system. Toxilogical studies conducted at ALZA during the past 2 years have not revealed limiting adverse effects of either the CHRONOMER materials or their hydrolysis products. The tail-flick test procedure was used to measure the effectiveness of naltrexone to antagonize the analgesis of morphine in rats. Naltrexone infused intravenously at doses of 4 and 16 ug/kg/hr resulted in, after 6 hours, 54 and 89 per cent antagonism, respectively, against a 63.5 per cent effective dose of morphine. Preliminary sterilization studies showed that no adverse effects to CHRONOMER/naltrexone systems occurred after exposure to 2.5 or 5.0 mrads of 60Co irradiation.
D000818:Animals; D001673:Biodegradation, Environmental; D004343:Drug Implants / Q000009:adverse effects; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D009020:Morphine / Q000037:antagonists & inhibitors; D009270:Naloxone / Q000031:analogs & derivatives*; D009271:Naltrexone / Q000008:administration & dosage* / Q000494:pharmacology; D011108:Polymers; D051381:Rats; D011930:Reaction Time / Q000187:drug effects
D004343:Drug Implants; D011108:Polymers; D009270:Naloxone; D009271:Naltrexone; D009020:Morphine